QPS Expands Into Toxicology Services With Acquisition of the Preclinical Unit of DCB Taiwan

By Qps Holdings Llc, PRNE
Sunday, February 13, 2011

NEWARK, Delaware and TAIPEI, Taiwan, February 14, 2011 - QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract
research organization providing testing services to support preclinical and
clinical research and development, announced the acquisition of the Center of
Toxicology and Preclinical Sciences (CTPS) from Taiwan's Development Center
for Biotechnology (DCB). CTPS, located in Taipei, will become a division of

QPS is a global CRO supporting drug discovery and development since 1995.
Its five areas of expertise include: Preclinical DMPK/Toxicology,
Bioanalytical, Translational Medicine, Early Stage Clinical and Late Stage
Clinical Research.

CTPS is an ISO/IEC 17025 certified, GLP compliant (Taiwan DOH, OECD) and
AAALAC accredited facility specializing in general nonclinical toxicity and
safety testing, genetic toxicology, reproductive toxicology, immunotoxicity
testing, biocompatibility testing, and DMPK studies. The center for
toxicology and preclinical services covers 5600 square meters (60,000 square
feet) and includes: seven laboratories, three culture rooms, a quality
assurance unit, archives, and two floors of animal housing.

In the past 12 years, DCB has conducted over 890 studies for local and
international clients, including 17 projects for US IND submissions, 18
projects for Taiwan IND submissions or clinical trials, and 2 products
seeking Taiwan NDA approval.

"The biotech industry in the Asia Pacific region is expanding rapidly,"
says Vincent Yen, President and CEO of QPS-Taiwan. "With the addition of a
well known toxicology unit to our established bioanalytical and
pharmacokinetic expertise, QPS can now provide a one-stop solution to the
increasing local and international demand for high quality preclinical
services. Along with our recent acquisitions in Europe and India, this
represents another step in building world-class global capabilities."

Dr. Walter Bee, QPS' new VP and Head of Global Safety Assessment and
Regulatory Affairs, brings to the table over 20 years of CRO and
Pharma/Biotech experience in Preclinical Development. He notes, "I'm thrilled
to be joining an organization that is as highly regarded and dynamic as QPS.
The addition of the DCB toxicology unit, a top-notch toxicology facility with
an admirable track record for providing first-rate, exacting service,
definitely enhances QPS' offerings for its clients worldwide."

About QPS

QPS provides GLP/GCP-compliant preclinical and clinical research services
to pharmaceutical and biotechnology clients worldwide in the areas of
Bioanalysis, Drug Metabolism and Pharmacokinetics, Translational Medicine,
and Clinical Research. Founded by Dr. Ben Chien in 1995, QPS has Bioanalysis
and Preclinical testing facilities at its Newark, DE headquarters; and
facilities in Groningen, the Netherlands; Taipei, Taiwan; and Hyderabad,
. Early-phase clinical facilities are located in Springfield, MO;
Taipei, Taiwan; Groningen, the Netherlands; and Hyderabad, India. Business
development offices are maintained in the US, Europe, and Asia.

About DCB

The Development Center for Biotechnology (DCB) of Taiwan was established
in 1984 with support from the Department of Industrial Technology (DOIT) and
the Ministry of Economic Affairs (MOEA). DCB's main mission was to help shape
and develop Taiwan's biotechnology industry through R&D,
infrastructure-building and training programs. DCB played the crucial role of
facilitator in promoting synergy among governmental, academic and industrial
efforts and served as an important bridge connecting Taiwan's biotech
industry with the world.


QPS, Ben Chien, PhD, Chairman, President & CEO, QPS Holdings, LLC, +1-650-599-9445 CA office, ben.chien at qps-usa.com; or Development Center for Biotechnology, Vincent Yen, CEO, QPS Taiwan, +886-2-2655-7555

will not be displayed